- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01952834
Effect of Probiotic Supplementation on Endothelial Function
December 15, 2015 updated by: Medical College of Wisconsin
Effect of Probiotic Supplementation on Endothelial Function in Men With Coronary Artery Disease
The study is being performed to determine whether probiotics (GoodBelly) improves blood vessel function.Probiotics similar to yogurt are living micro-organisms (beneficial to its host) the lives in the intestine.
Patients who have coronary artery disease will be enrolled in this study.
The research results will be used to determine if the type of bacteria present in the intestines play a role in the pathogenesis of cardiovascular disease.
Patients with coronary artery disease will be enrolled for up to 12 weeks.
Patients will take the probiotic for 6 weeks.
Following the 6 week period there is a washout period of 4 weeks, and an optional antibiotic study called vancomycin.
Patients will take the vancomycin for 10 days.
Blood vessel function will be measured by ultrasound before and after the probiotic supplement and vancomycin antibiotic.
Blood will also be taken before and after to evaluate for markers of inflammation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
We plan to recruit 20 patients, men with coronary artery disease, for this single center, interventional trial with the Probiotic-GoodBelly followed by Vancomycin.
The study includes 6 total visits.
Subjects who pass a phone screen will be invited to a screening visit for study eligibility (Visit 1) Informed consent will be reviewed; a unique study number will be assigned once written informed consent is obtained (no subject will be assigned more than 1 allocation number); relevant participant medical history will be recorded including currently prescribed medications; anthropometric measurements will be taken (height, weight, and waist circumference in metric units) and blood pressure will be recorded (measured in triplicate and averaged).
Subjects will be allowed to take their blood pressure medication on the morning of their screening visit, but not the mornings of any of the other study visits to limit the acute influence of these medications on endothelial function.
If the potential participant qualifies for the study, he will return 1 week after the screen for a study visit(Visit 2) where he will turn in his stool sample, undergo initial tests of endothelial function and receive 3 week supply of GoodBelly Probiotic.
After 3 weeks he will have to return (Visit 3) for another 3 week supply of his probiotic.
After a total of 6 weeks of taking the probiotic he will have to return (Visit 4) with his stool sample.
He will be asked to fast for 6-8 hours prior to the visit to limit the acute dietary influences on vascular endothelial function.
During Visit 4, endothelial function will determined by brachial artery reactivity testing His stool samples will be collected and blood samples will also be taken at this visit for systemic measurements inflammatory markers.
If he agrees to the optional Vancomycin study.
He will return after 4 weeks for (Visit 5).
He will be asked to fast for 6-8 hours prior to the visit to limit the acute dietary influences on vascular endothelial function.
At Visit 5, endothelial function will determined by brachial artery reactivity testing His stool samples will be collected and blood samples will also be taken at this visit for systemic measurements inflammatory markers.
He will then be given a 10 day supply of vancomycin.
After 10 days he will return (Visit 6) with his stool sample.
At Visit 6, endothelial function will determined by brachial artery reactivity testing .
His stool samples will be collected and blood samples will also be taken at this visit for systemic measurements inflammatory markers.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Milwauke, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Age between 40-75 years old
- Male sex
- History of known coronary artery disease (by either history of myocardial infarction, angiogram demonstrative >=50% stenosis in at least 1 major epicardial coronary artery, or a previous stress test that showed evidence of ischemia that has not been revealed to be a false positive test by angiography)
Exclusion Criteria:
- Unstable angina or myocardial infarction by history, ECG, and/or enzymatic criteria within 1 month of enrollment.
- Left ventricular dysfunction as defined by an left ventricular ejection fraction documented as < 45% within 1 year of enrollment by an echocardiogram, MRI, or nuclear imaging.
- Uncontrolled hypertension with a blood pressure greater than 170/100 mmHg at the screening visit.
- Known history of chronic renal insufficiency, liver dysfunction, or cancer besides non-melanoma skin carcinomas or localized prostate cancer requiring systemic treatment within five years of enrollment.
- Known history of cognitive impairment or inability to follow study procedures
- Patient with an implanted defibrillator or permanent pacemaker on with the potential participant is known to rely upon for greater than 50% of ventricular depolarizations.
- Patients who received probiotics, prebiotics, and antibiotics in the last 12 weeks.
- Patients with dosing changes of vasoactive medications and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the 6 weeks prior to enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: GoodBelly Probiotic and Vancomycin
Good Belly Probiotic 2.7 oz Daily x 6 weeks Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
|
GoodBelly Probiotic 2.7 oz Daily x 6 weeks.
Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
GoodBelly Probiotic 2.7 oz Daily x 6 weeks.
Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brachial Artery Flow Mediated Dilation
Time Frame: % Change before and after 6 weeks of daily Probiotic
|
A measurement of endothelial function in humans that reports the percent change in brachial artery diameter to a flow stimulus in the arm induced by 5 minutes of occlusion of flow to the arm.
It is measured as the percent change from baseline diameter.
|
% Change before and after 6 weeks of daily Probiotic
|
|
Brachial Artery Flow Mediated Dilation
Time Frame: Change before and after 10 days of Vancomycin, approximately 12 weeks from baseline
|
Flow Mediated Dilation is measured as the percent change in brachial artery diameter as measured by high resolution ultrasound based on arterial diameter prior to and following 5 minute flow occlusion to the forearm .
We measured the percent change in brachial diameter before vancomycin was started and again 10 days after vancomycin
|
Change before and after 10 days of Vancomycin, approximately 12 weeks from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interleukin 8
Time Frame: Change before and after 6 weeks of daily Probiotic
|
Circulating cytokine measured in the plasma
|
Change before and after 6 weeks of daily Probiotic
|
|
Interleukin-12
Time Frame: Change before and after 6 weeks of probiotic
|
This is a circulating plasma cytokine
|
Change before and after 6 weeks of probiotic
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michael E Widlansky, MD, Medical College of Wisconsin
- Principal Investigator: John Baker, PhD, Medical College of Wisconsin
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
March 1, 2015
Study Completion (Actual)
March 1, 2015
Study Registration Dates
First Submitted
September 24, 2013
First Submitted That Met QC Criteria
September 24, 2013
First Posted (Estimate)
September 30, 2013
Study Record Updates
Last Update Posted (Estimate)
January 21, 2016
Last Update Submitted That Met QC Criteria
December 15, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO00019610
- FP00004156 (Other Identifier: CTSI Advancing a Healthier Wisconsin)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Infirmerie Protestante de LyonRecruitingCoronary Artery Bypass | Coronary Artery Disease(CAD) | Off Pump Coronary Artery Bypass Surgery | Hemodynamic Optimization | Hemodynamic Management | Off Pump Coronary Artery Bypass Graft | Coronary Artery Disease With Need for Bypass Surgery | NoradrenalineFrance
-
Shanghai Bluesail Boyuan Medical Technology Co....Not yet recruitingCoronary Artery Disease | Coronary Artery Calcification | Severe Coronary Artery DiseaseChina
-
Scitech Produtos Medicos SANot yet recruitingCoronary Artery Disease (CAD) | Multivessel Coronary Artery Disease | Complex Coronary Lesions | Calcific Coronary Arteriosclerosis | Small Vessel Ischemic Disease | Stenosis CoronaryBrazil
-
Istanbul Mehmet Akif Ersoy Educational and Training...Bakirkoy Dr. Sadi Konuk Research and Training Hospital; Ege University; Istanbul... and other collaboratorsActive, not recruitingCoronary Artery Disease (CAD) | Coronary Bifurcation Lesion | Left Main Coronary Artery StenosisTurkey (Türkiye)
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioCompletedCoronary Artery Disease (CAD) | Atherosclerosis of Coronary ArteryItaly
-
EBI Anti Sepsis BVCR2O B.V.Not yet recruitingCoronary Artery Disease (CAD) | Coronary Artery Bypass Graft Surgery(CABG)United States, Netherlands, Belgium, United Kingdom
-
University Medical Centre LjubljanaRecruitingCoronary Artery Disease With Myocardial InfarctionSlovenia
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Shunmei MedicalNot yet recruitingCalcified Coronary Artery Disease | Coronary Arterial DiseasePoland, France, Spain
-
OPCI Core Laboratories LLCNot yet recruitingCoronary Artery Disease (CAD) | Coronary Calcification | Coronary Calcified Disease | Coronary Calcified NodulesUnited States
Clinical Trials on GoodBelly Probiotic
-
Medical College of WisconsinCompletedCoronary Artery Disease | Hypertension | Peripheral Vascular Diseases | Hyperlipidemias | Cerebral Arterial DiseasesUnited States
-
Medical College of WisconsinCompletedCardiovascular Disease | Diabetes Mellitus, Type 2United States
-
King's College Hospital NHS TrustCompleted
-
Lallemand Health SolutionsRecruitingFocus is on Healthy SubjectsCanada
-
Fudan UniversityInner Mongolia Yili Industrial Group Co., LtdCompletedObesity | AdiposityChina
-
Maastricht University Medical CenterCompleted
-
BiocodexCompletedAcute GastroenteritisArgentina
-
Fundació Sant Joan de DéuCompleted
-
University of LeedsUnknown
-
Centro Pediatrico Albina de PatinoCompletedAcute Gastroenteritis | Acute DiarrheaBolivia